Supplementary Figure S3 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

Supplementary Figure S3 shows infiltration of immune cells in the tumor tissues after treatment with P1A-T cells with anti-PD-1 mAb.</p

Supplementary Figure S2 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

Supplementary Figure S2 shows a diminished PD-1 expression on Pdcd1 gene-knockdown 7Ã-19 P1A-T cells.</p

Supplementary Figure S6 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

Supplementary Figure S6 shows an expression of human CD20 on hCD20-P815 tumor cells.</p

Supplementary Figure S4 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

Supplementary Figure S4 shows the effects of anti-PD-1 mAb combination on the generation of memory T cell responses.</p

Supplementary Figure S5 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

Supplementary Figure S5 shows the generation of long-term anti-tumor memory responses in vivo by 7Ã-19 P1A-T cell therapy.</p

Supplementary Figure S1 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

Supplementary Figure S1 shows an indispensable role of tumor specificity of TCR in the anti-tumor efficacy of IL-7/ CCL19-producing T cells.</p